Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded to “Hold” at StockNews.com
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Monday. CRVS has been the topic of several other reports. Oppenheimer restated an “outperform” rating and set a $17.00 target price (up from $15.00) on shares of […]
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Monday. CRVS has been the topic of several other reports. Oppenheimer restated an “outperform” rating and set a $17.00 target price (up from $15.00) on shares of […]
